As Roivant readies for a UC clash with Merck, CEO Matt Gline is candid about keeping a competitive edge
Roivant CEO Matt Gline is getting ready for a development showdown with Merck and its newly acquired ulcerative colitis drug from Prometheus Biosciences.
On Thursday, Roivant released new Phase IIb data for RVT-3101, the UC program it acquired from Pfizer late last year, showing that the drug’s effects could be maintained for up to a year. It’s confirmation of earlier data showing success at 14 weeks — a statistically significant finding, Roivant said in January.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.